Final answer:
For STEMI patients, the administration of anti-platelet therapy, specifically dual anti-platelet therapy with clopidogrel and aspirin for 48 hours, is crucial following fibrinolytic therapy to reduce cardiovascular events and promote vessel healing.
Step-by-step explanation:
Patients with STEMI undergoing reperfusion with fibrinolytic therapy should receive anti-platelet therapy for 48 hours. This therapy typically includes a combination of clopidogrel and aspirin, known as dual anti-platelet therapy, which is more effective than aspirin alone in reducing cardiovascular events in those with a STEMI. Fibrinolytic therapy involves the use of thrombolytic agents that aim to dissolve the blood clot impeding blood flow by converting plasminogen into plasmin, leading to the breakdown of fibrin within the clot. This process is critical for restoring normal blood flow and allowing the vessel to heal properly.